Ngā hua rapu - Rahul Banerjee

  • E whakaatu ana i te 1 - 3 hua o te 3
Whakamahine hua
  1. 1
    A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma

    A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma mā Alfred L. Garfall, Rahul Banerjee, Laurent Frenzel, Cyrus Khandanpour, Cyrus Khandanpour, Cyrus Khandanpour, Yi Lin, Erica Ottoni, Robert Rifkin, Sarah Rockwell, Cesar Rodriguez, Humberto Villefort, Elena Zamagni, Elena Zamagni

    I whakaputaina 2025-07-01

    IntroductionBispecific antibodies (BsAbs) are novel immunotherapy agents for the treatment of relapsed/refractory multiple myeloma (RRMM). Currently, 3 BsAbs (teclistamab, talquetamab, and elranatamab) are approved for the treatment of RRMM. Administering BsAbs in different practice settings is cruc...

    Whakaahuatanga katoa

    Whiwhi kuputuhi katoa
    Tuhinga

    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

    Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immun... mā Danai Dima, Mariola A. Vazquez-Martinez, James A. Davis, Utkarsh Goel, Aimaz Afrough, Aishwarya Sannareddy, Oren Pasvolsky, Beatrice Razzo, Rahul Banerjee, Jack Khouri, Ariel Grajales-Cruz, Alex Lieberman-Cribbin, Masooma Shifa Rana, Kelley Julian, Shaun DeJarnette, Andrew J. Portuguese, Mahmoud R. Gaballa, Gabriel De Avila, Sandra Susaniba Adaniya, Shahzad Raza, Megan M. Herr, Evguenia Ouchveridze, Tiffany Richards, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Omar Castaneda Puglianini, Adriana Rossi, Yi Lin, Shebli Atrash, Douglas Sborov, Kenneth H. Shain, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Doris K. Hansen, Surbhi Sidana, Krina K. Patel, Andrew J. Cowan, Larry D. Anderson, Hans C. Lee, Faiz Anwer, Christopher J. Ferreri, Leyla Shune

    I whakaputaina 2025-06-01

    Abstract Data describing outcomes of teclistamab in multiple myeloma patients with prior exposure to BCMA-directed therapy (BCMA-DT) are limited. The goal of this multicenter retrospective analysis was to report the efficacy and safety of standard-of-care teclistamab in patients with prior BCMA-DT....

    Whakaahuatanga katoa

    Whiwhi kuputuhi katoa
    Tuhinga

    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

    Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment mā Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F. Grajales-Cruz, Jack Khouri, Kelley Julian, Oren Pasvolsky, Rahul Banerjee, Beatrice Razzo, Christopher J. Ferreri, Mariola A. Vazquez-Martinez, James A. Davis, Aishwarya Sannareddy, Omar Castaneda, Shahzad Raza, Andrew J. Portuguese, Mahmoud R. Gaballa, Masooma S. Rana, Alex Lieberman-Cribbin, Shaun DeJarnette, Rebecca Gonzalez, Anna Chen, Megan M. Herr, Lekha Mikkilineni, Hitomi Hosoya, Evguenia Ouchveridze, Gurbakhash Kaur, Adriana Rossi, Leyla Shune, Faiz Anwer, Yi Lin, Shambavi Richard, Douglas W. Sborov, Rachid C. Baz, Alfred L. Garfall, Hans C. Lee, Larry D. Anderson, Jr., Andrew J. Cowan, Krina K. Patel, Peter M. Voorhees, Surbhi Sidana, Doris K. Hansen, Shebli Atrash, Sandra P. Susanibar-Adaniya

    I whakaputaina 2025-07-01

    Abstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was...

    Whakaahuatanga katoa

    Whiwhi kuputuhi katoa
    Tuhinga

    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: